These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 13947776)

  • 1. Spurious elevation of urinary catecholamines during therapy with alpha-methyl-dopa. A diagnostic pitfall.
    GIFFORD RW; TWEED DC
    JAMA; 1962 Oct; 182():493-5. PubMed ID: 13947776
    [No Abstract]   [Full Text] [Related]  

  • 2. [EFFECT OF THE DOPA-DECARBOXYLASE INHIBITOR ALPHA-METHYLDOPA ON THE INCORPORATION OF DOPA INTO MELANIN AND PYROCATECHOLAMINE. IN VIVO STUDIES ON MELANOMA MICE WITH TRITIATED DOPA].
    HEMPEL K; DEIMEL M
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1963 Nov; 246():203-14. PubMed ID: 14095447
    [No Abstract]   [Full Text] [Related]  

  • 3. EFFECT OF ALPHA-METHYL-DOPA ON MYOCARDIAL CATECHOLAMINES.
    MAITRE L; STAEHELIN M
    Experientia; 1963 Nov; 19():573-5. PubMed ID: 14101511
    [No Abstract]   [Full Text] [Related]  

  • 4. [The effect of intravenously administered DOPA on the blood pressure in pretreated alpha-methyl-DOPA hypertensives. Studies on the blood pressure-lowering mechanism of alpha-methyl-DOPA].
    SCHAER H; ZIEGLER WH
    Klin Wochenschr; 1962 Sep; 40():959-62. PubMed ID: 13976633
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical evaluation of alpha methyl-dopa.
    SPERBER RJ; DEGRAFF AC
    Am Heart J; 1963 Feb; 65():275-6. PubMed ID: 13990064
    [No Abstract]   [Full Text] [Related]  

  • 6. Alpha methyl dopa in the treatment of hypertension.
    DOYLE A; TREVAKS G
    Med J Aust; 1962 Jul; 49(2)():55-6. PubMed ID: 13887654
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of alpha-methyl DOPA in severe and malignant hypertension.
    CANNON PJ; WHITLOCK RT; MORRIS RC; ANGERS M; LARAGH JH
    JAMA; 1962 Mar; 179():673-81. PubMed ID: 13876240
    [No Abstract]   [Full Text] [Related]  

  • 8. [Value of alpha-methyl-dopa for the treatment of chronic hypertension].
    ARNOLD OH
    Dtsch Med Wochenschr; 1962 Apr; 87():844-8. PubMed ID: 13862447
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical and chemical studies with alpha-methyl-dopa in patients with hypertension.
    GILLESPIE L; OATES JA; CROUT JR; SJOERDSMA A
    Circulation; 1962 Feb; 25():281-91. PubMed ID: 13898638
    [No Abstract]   [Full Text] [Related]  

  • 10. [Evaluation of the hypotensive effect of aldomet (alpha-methyl DOPA) in the treatment of arterial hypertension, with reference to its effect on the metabolism of catecholamines].
    ALEKSANDROW D; JANUSZEWICZ W; WOCIAL B
    Pol Tyg Lek; 1962 Nov; 17():1841-43. PubMed ID: 14011861
    [No Abstract]   [Full Text] [Related]  

  • 11. [THE ROLE OF CATECHOLAMINES IN THE CONTROL OF HYPOTHALAMIC NEUROSECRETION. EFFECTS OF RESERPINE COMPOUNDS, MONOAMINE OXIDASE INHIBITORS AND D-1 DOPA 5-HTP DECARBOXYLASE INHIBITORS].
    CAHN J; HEROLD M
    Agressologie; 1964; 5():451-63. PubMed ID: 14192331
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of L-alpha-methyl DOPA and N-2-hydroxybenzyl-N-methyl hydrazine (NSD 1039) on the blood pressure of renal hypertensive rates.
    DAVIS RA; DRAIN DJ; HORLINGTON M; LAZARE R; URBANSKA A
    Life Sci (1962); 1963 Mar; 3():193-7. PubMed ID: 14025509
    [No Abstract]   [Full Text] [Related]  

  • 13. [alpha-Methyl-DOPA. Therapeutic experiences in hypertension and biochemical research on its mode of action].
    SCHAUB F; NAGER F; SCHAER H; ZIEGLER W; LICHTLEN P
    Schweiz Med Wochenschr; 1962 May; 92():620-8. PubMed ID: 14498080
    [No Abstract]   [Full Text] [Related]  

  • 14. [Preliminary report on the clinical effectiveness of 1-alpha-methyl-DOPA (Aldomet) in the treatment of hypertension].
    FELLINGER K; GRABNER G; KRYGICZ H
    Wien Z Inn Med; 1961 Dec; 42():527-30. PubMed ID: 13892223
    [No Abstract]   [Full Text] [Related]  

  • 15. [The use of the combination of L-alpha-methyldopa and dichlorothiazide in the treatment of arterial hypertension].
    BAILA MR; CINTAS JA
    Dia Med; 1962 Dec; 34():2422-4. PubMed ID: 13969004
    [No Abstract]   [Full Text] [Related]  

  • 16. Dopa, 3-O-methyldopa, and metabolites in urine during oral L-3-O-methyldopa therapy.
    Sharpless NS; Tyce GM; Muenter MD; Dinapoli RP
    Clin Pharmacol Ther; 1974 Nov; 16(5 Part 1):770-81. PubMed ID: 4426145
    [No Abstract]   [Full Text] [Related]  

  • 17. The acute hemodynamic eeffects of alpha-methyldopa in man.
    WILSON WR; FISHER FD; KIRKENDALL WM
    J Chronic Dis; 1962 Sep; 15():907-13. PubMed ID: 14001103
    [No Abstract]   [Full Text] [Related]  

  • 18. Methyldopa in hypertension.
    DOLLERY CT
    Am Heart J; 1963 Jan; 65():139-40. PubMed ID: 14028479
    [No Abstract]   [Full Text] [Related]  

  • 19. Guanethidine and methyldopa as therapeutic agents in hypertension. A comparative review.
    GOLDBERG LI; ZIMMERMAN AM
    Postgrad Med; 1963 Jun; 33():548-54. PubMed ID: 13948676
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacodynamic effects and clinical use of alpha methyldopa in the treatment of essential hypertension.
    ONESTI G; BREST AN; NOVACK P; MOYER JH
    Am J Cardiol; 1962 Jun; 9():863-7. PubMed ID: 14482028
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.